Menu Menu


AZN Financials       Clear


AZN        0000901832    
Filing Date Form Type Description Document
2026-11-02 6-K ADMISSION OF FURTHER SECURITIES TO TRADING View Document
2026-11-02 6-K TOTAL VOTING RIGHTS View Document
2026-10-30 6-K 3RD QUARTER RESULTS View Document
2026-10-27 6-K ENHERTU APPROVED IN EU FOR HER2-POSITIVE EBC View Document
2026-10-22 6-K ULTOMIRIS APPROVED IN US IN IGAN View Document
2026-10-08 4 PRIMARY DOCUMENT View Document
2026-10-05 6-K ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT View Document
2026-10-02 6-K AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY View Document
2026-10-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING View Document
2026-10-01 6-K TOTAL VOTING RIGHTS View Document
2026-09-29 6-K ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT View Document
2026-09-23 6-K TRIXEO APPROVED IN EU FOR ASTHMA View Document
2026-09-21 6-K KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP View Document
2026-09-21 6-K ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC View Document
2026-09-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-15 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-09-14 6-K UPDATE ON SERENA-4 PHASE III TRIAL View Document
2026-09-11 4 OWNERSHIP DOCUMENT View Document
2026-09-08 6-K IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG View Document
2026-09-08 6-K ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER View Document
2026-09-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING View Document
2026-09-01 6-K TOTAL VOTING RIGHTS View Document
2026-09-01 6-K ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING View Document
2026-09-01 6-K ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC View Document
2026-09-01 6-K DIRECTORATE CHANGE View Document
2026-09-01 6-K ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY View Document
2026-09-01 6-K TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG View Document
2026-08-27 6-K TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS View Document
2026-08-25 6-K ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING View Document
2026-08-19 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-08-17 6-K ENHERTU IMPROVED PFS IN 1L HER2M LUNG CANCER View Document
2026-08-17 6-K UPDATE ON EVOLVE-LUNG02 PHASE III TRIAL View Document
2026-08-17 6-K TAGRISSO+ORPATHYS IMPROVED PFS & OS IN EGFRM LUNG View Document
2026-08-07 4 PRIMARY DOCUMENT View Document
2026-08-03 6-K ADMISSION OF FURTHER SECURITIES TO TRADING View Document
2026-08-03 6-K TOTAL VOTING RIGHTS View Document
2026-07-31 6-K DATROWAY APPROVED IN EU FOR TNBC View Document
2026-07-27 6-K FORM 6-K View Document
2026-07-27 6-K UPDATE ON ULTOMIRIS PHASE III TRIAL IN HSCT-TMA View Document
2026-07-27 6-K SONE-VE IMPROVED SURVIVAL IN GASTRIC CANCERS View Document
2026-07-23 6-K ETCAMAH APPROVED IN THE EU FOR ER+ BREAST CANCER View Document
2026-07-14 6-K ASTRAZENECA LICENSES NOVEL EGFR INHIBITOR View Document
2026-07-09 6-K UPDATE ON CARDIO-TTRANSFORM PHASE III TRIAL View Document
2026-07-08 4 OWNERSHIP DOCUMENT View Document
2026-07-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING View Document
2026-07-01 6-K TOTAL VOTING RIGHTS View Document
2026-06-29 11-K FORM 11-K View Document
2026-06-29 6-K ENHERTU APPROVED IN EU FOR HER2+ SOLID TUMOURS View Document
2026-06-29 6-K DATROWAY RECOMMENDED FOR APPROVAL IN EU FOR TNBC View Document
2026-06-16 4 OWNERSHIP DOCUMENT View Document
2026-06-15 6-K TRUQAP APPROVED IN US FOR PROSTATE CANCER View Document
2026-06-01 6-K ADMISSION OF FURTHER SECURITIES TO TRADING View Document
2026-06-01 6-K TOTAL VOTING RIGHTS View Document
2026-05-29 6-K IMFINZI APPROVED IN US FOR EARLY BLADDER CANCER View Document
2026-05-28 25-NSE View Document
2026-05-27 6-K US FDA DECISION DATE ON CAMIZESTRANT EXTENDED View Document
2026-05-26 6-K DATROWAY APPROVED IN US FOR 1L TRIPLE-NEGATIVE BC View Document
2026-05-26 6-K ENHERTU RECOMMENDED IN EU FOR HER2+ SOLID TUMOURS View Document
2026-05-26 6-K CAMIZESTRANT RECOMMENDED FOR BREAST CANCER IN EU View Document
2026-05-22 4 OWNERSHIP DOCUMENT View Document
2026-05-18 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-05-18 6-K BAXFENDY APPROVED IN THE US FOR HYPERTENSION View Document
2026-05-18 6-K ENHERTU APPROVED IN TWO HER2+ EARLY BC SETTINGS View Document
2026-05-14 6-K IMFINZI + EV IMPROVES EFS & OS IN BLADDER CANCER View Document
2026-05-08 4 OWNERSHIP DOCUMENT View Document
2026-05-01 6-K TOTAL VOTING RIGHTS AND ADMISSION OF SHARES View Document
2026-05-01 6-K FDA ODAC VOTE ON CAMIZESTRANT IN BREAST CANCER View Document
2026-05-01 6-K FDA ODAC RECOMMENDS TRUQAP IN PROSTATE CANCER View Document
2026-04-29 6-K 1ST QUARTER RESULTS View Document
2026-04-28 SCHEDULE 13G View Document
2026-04-28 6-K BREZTRI APPROVED IN THE US FOR ASTHMA View Document
2026-04-27 6-K SAPHNELO SELF-ADMINISTRATION APPROVED IN THE US View Document
2026-04-23 6-K DIRECTORATE CHANGE View Document
2026-04-21 6-K I CAN PHIII INTERIM ANALYSIS MET PRIMARY ENDPOINT View Document
2026-04-20 6-K THIRD TOZORAKIMAB POSITIVE PHASE III IN COPD View Document
2026-04-09 6-K RESULT OF AGM View Document
2026-04-08 25-NSE View Document
2026-04-02 6-K IMFINZI+IMJUDO IMPROVES PFS IN EARLY LIVER CANCER View Document
2026-04-01 6-K TOTAL VOTING RIGHTS AND ADMISSION OF SHARES View Document
2026-03-31 6-K EFZIMFOTASE ALFA PH3 PROGRAM SHOW POSITIVE RESULTS View Document
2026-03-27 6-K TOZORAKIMAB MET OBERON/TITANIA PRIMARY ENDPOINTS View Document
2026-03-20 6-K NOTIFICATION OF ADMISSION OF SHARES View Document
2026-03-19 3 OWNERSHIP DOCUMENT View Document
2026-03-16 6-K IMFINZI APPROVED IN EU FOR EARLY GASTRIC CANCER View Document
2026-03-10 6-K NOTICE OF AGM View Document
2026-03-10 6-K FORM 6-K View Document
2026-03-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-06 6-K DIRECTOR/PDMR SHAREHOLDING View Document
2026-03-04 CERT NYSE CERTIFICATION View Document
2026-03-03 8-A12B FORM 8-A12B View Document
2026-03-02 6-K FORM 6-K View Document
2026-03-02 6-K TOTAL VOTING RIGHTS View Document
2026-02-27 424B2 424B2 View Document
2026-02-26 6-K ASTRAZENECA PRICES A $2BN BOND OFFERING View Document
2026-02-26 FWP FWP View Document
2026-02-25 6-K FILING OF FORM 20-F WITH SEC View Document
2026-02-25 424B2 424B2 View Document
2026-02-24 IRANNOTICE IRANNOTICE View Document

Find registration statements, periodic reports, and other forms by typing ticker symbol of a company.

Ticker:

(402) 804-8299